Sabah Sallah

Prior to joining Genespire, Sabah served as senior vice president in gene therapy, hematology and translational medicine at Freeline Therapeutics. In his capacity as senior vice president, he had the oversight of disease-target identification, translation of the pre-clinical evidence to clinical development and ensuring the alignment between the clinical, pre-clinical and regulatory and other functions across the company.

Prior to Freeline Therapeutics, he served as vice president, clinical development at uniQure where he had the responsibility of the design and implementation of the phase IIB and phase III clinical trials in treatment of hemophilia B with AAV5-FIX -Padua based liver targeted gene transfer. In addition, he had the oversight of the design of the Pediatric Investigational Plan and the evaluation of translatability of in vitro and animal studies to human.

Prior to uniQure, Sabah was executive director in clinical development and medical affairs at Novo Nordisk with focus on the development of recombinant proteins in hemophilia and other rare disorders. Overall, his tenure in pharmaceuticals spanned the United States, Europe and several other international markets. He has contributed to the development and global approval of at least 6 products in various rare disorders.